Clinical particularities of pregnancy in the periodic disease and special considerations in the prenatal care

The problem of studying the periodic disease (PD) has almost a centennial history. A new stage in diagnosing and evaluating the prevalence of the PD in various populations was due to an essential discovery of the MEFV (MEditerranean FeVer) gene localized in the chromosome 16p13.3. Colchicine remains the only officially accepted medicine for PD treatment and renal amyloidosis prevention. However, from the perspective of the perinatal pharmacotherapy with a glance to colchicine’s teratogenic effect its use in obstetrics is inappropriate.

KanJang®, ImmunoGuard®, periodic disease, colchicines, KanJang®, ImmunoGuard®